<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>1497</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>9060611</PubmedId>
            <Abstract>An analysis was made of the neutralizing antibody repertoire, for influenza virus hemagglutinin (HA) of transgenic mice expressing a human immunoglobulin mu (IgH) minigene, by monoclonal antibody (MAb) selection and sequencing of the HA genes of X31 (H3N2 subtype) laboratory variants. Whereas previously reported laboratory variants, selected in ovo with high-affinity murine MAbs of the IgG class, differed from wild-type virus by a single amino acid residue change in one of the major antigenic sites, neutralizing MAbs from transgenic donors selected novel variant viruses with altered receptor-binding specificity and contained residue changes in both the receptor-binding pocket (HA1 225 or HA1 226) and an antigenic site (HA1 135, HA1 145, or HA1 158). Changes in receptor-binding specificities of the variant viruses were confirmed by their resistance to inhibition by horse serum glycoproteins and altered binding to neoglycoproteins. The residue changes in variant virus V-21.2 (HA1 135 G--&gt;R, 225 G--&gt;D) abrogated neutralization by each of the MAbs; nevertheless V-21.2 was recognized by its own selecting MAb in enzyme-linked immunosorbent assay and therefore qualified as an adsorptive mutant rather than an antigenic variant. We consider that a low-affinity neutralizing antibody response may preferentially select for receptor-binding variants of influenza virus HA.</Abstract>
            <ArticleYear>1997</ArticleYear>
            <ArticlePages>2600-5</ArticlePages>
            <ArticleTitle>Preferential selection of receptor-binding variants of influenza virus hemagglutinin by the neutralizing antibody repertoire of transgenic mice expressing a human immunoglobulin mu minigene.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Laeeq</LastName>
                    <ForeName>S</ForeName>
                </Author>
                <Author>
                    <LastName>Smith</LastName>
                    <ForeName>C A</ForeName>
                </Author>
                <Author>
                    <LastName>Wagner</LastName>
                    <ForeName>S D</ForeName>
                </Author>
                <Author>
                    <LastName>Thomas</LastName>
                    <ForeName>D B</ForeName>
                </Author>
            </Authors>
            <Affiliations>National Institute for Medical Research, London, United Kingdom.</Affiliations>
            <ArticleChemicalList>Antibodies, Monoclonal;Antibodies, Viral;Glycoconjugates;Hemagglutinin Glycoproteins, Influenza Virus;Immunoglobulin mu-Chains;Receptors, Virus;N-Acetylneuraminic Acid</ArticleChemicalList>
            <ArticleMeshHeadingsList>Animals; Antibodies, Monoclonal(genetics; immunology); Antibodies, Viral(genetics; immunology); Antibody Specificity; Chick Embryo; Cross Reactions; Enzyme-Linked Immunosorbent Assay; Genetic Variation; Glycoconjugates(immunology); Hemagglutination Inhibition Tests; Hemagglutinin Glycoproteins, Influenza Virus(genetics; immunology); Humans; Immunoglobulin mu-Chains(genetics; immunology); Influenza A virus(genetics; immunology; metabolism); Mice; Mice, Nude; Mice, Transgenic; Molecular Structure; N-Acetylneuraminic Acid(immunology); Phenotype; Receptors, Virus(immunology; metabolism)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>71</Volume>
                <Issue>4</Issue>
                <Title>Journal of virology</Title>
                <Issn>1098-5514</Issn>
                <MedlineTa>J Virol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>HA - mAb 7.1</EpitopeName>
                <EpitopeStructure>
                    <DiscontinuousRegionOnAccessionSequenceMolecule>
                        <ChemicalType>Discontinuous protein residues</ChemicalType>
                        <DiscontinuousResidues>G151, S161, G241, L242</DiscontinuousResidues>
                        <SourceMolecule>
                            <GenBankId>P03438.2</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>132504</SourceOrganismId>
                    </DiscontinuousRegionOnAccessionSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Tables 3 and 4</LocationOfData>
                <EpitopeId>107275</EpitopeId>
                <ReferenceRegion>G135, S145, G225, L226</ReferenceRegion>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Partial Epitope</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 5</LocationOfData>
                        <BCellId>1004099</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000247</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>132504</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>UV-irradiated X-31</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>1 dose of 10,000 HAU followed by a boost with 1,000 HAU 6 weeks later.</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>231</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Escape mutants selected with the mAb, derived from human IgM expressing mice, were sequenced to determine the epitope. Also the  and its neuramidase treated mAbs were used. This mAb selected residues G151 and G242 in two rounds of selection and S161 and L243 in one round. The laboratory variants and those selected with other mAbs carrying mutations in one or more of these residues were also less well recognized by this mAb in HI and ELISA, confirming the results. The mAb also had no or lower HI activity towards JAP/57 (subtype H2), PR8/34 (subtype H1) and H3 subtype viruses ENG/69, HK/71 and TEX/77.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Ascitic Fluid</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>mAb 7.1</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>132504</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>HA - mAb 21.2</EpitopeName>
                <EpitopeStructure>
                    <DiscontinuousRegionOnAccessionSequenceMolecule>
                        <ChemicalType>Discontinuous protein residues</ChemicalType>
                        <DiscontinuousResidues>G151, G241</DiscontinuousResidues>
                        <SourceMolecule>
                            <GenBankId>P03438.2</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>132504</SourceOrganismId>
                    </DiscontinuousRegionOnAccessionSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Tables 3 and 4</LocationOfData>
                <EpitopeId>107274</EpitopeId>
                <ReferenceRegion>G135, G225</ReferenceRegion>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Partial Epitope</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 5</LocationOfData>
                        <BCellId>1645145</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000247</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>132504</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>UV-irradiated X-31</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>1 dose of 10,000 HAU followed by a boost with 1,000 HAU 6 weeks later.</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>231</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Escape mutants selected with the mAb, derived from human IgM expressing mice, were sequenced to determine the epitope. Also the  and its neuramidase treated mAbs were used. This mAb selected residues G151 and G241 in two rounds of selection. The laboratory variants and those selected with other mAbs carrying mutations in one or more of these residues were also less well recognized by this mAb in HI, as well as those carrying mutations in the nearby residues S161 and L242. Nevertheless, the variants were still recognized by the mAb in ELISA. The mAb also had no or lower HI activity towards JAP/57 (subtype H2), PR8/34 (subtype H1) and H3 subtype virus TEX/77.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Ascitic Fluid</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>mAb 21.2</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>132504</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>HA - mAb 1.1</EpitopeName>
                <EpitopeStructure>
                    <DiscontinuousRegionOnAccessionSequenceMolecule>
                        <ChemicalType>Discontinuous protein residues</ChemicalType>
                        <DiscontinuousResidues>G151, S161, G174</DiscontinuousResidues>
                        <SourceMolecule>
                            <GenBankId>P03437.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>132504</SourceOrganismId>
                    </DiscontinuousRegionOnAccessionSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Tables 3 and 4</LocationOfData>
                <EpitopeId>107272</EpitopeId>
                <ReferenceRegion>G135, S145, G158</ReferenceRegion>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Partial Epitope</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 5</LocationOfData>
                        <BCellId>1645146</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000247</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>132504</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>UV-irradiated X-31</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>1 dose of 10,000 HAU followed by a boost with 1,000 HAU 6 weeks later.</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>231</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Escape mutants selected with the mAb, derived from human IgM expressing mice, were sequenced to determine the epitope. Also the and its neuramidase treated mAbs were used. This mAb selected residues G151 and G174 in one round of selection and residues S161 and G174 in another. The laboratory variants and those selected with other mAbs carrying mutations in one or more of these residues were also less well recognized by this mAb in HI and ELISA, as well as those carrying a mutation in the nearby residue L242. The mAb also had no or lower HI activity towards JAP/57 (subtype H2), PR8/34 (subtype H1) and H3 subtype viruses HK/71, PC/73, VIC/75 and TEX/77.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Ascitic Fluid</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>mAb 1.1</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>132504</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>HA - mAb 4.1</EpitopeName>
                <EpitopeStructure>
                    <DiscontinuousRegionOnAccessionSequenceMolecule>
                        <ChemicalType>Discontinuous protein residues</ChemicalType>
                        <DiscontinuousResidues>G151</DiscontinuousResidues>
                        <SourceMolecule>
                            <GenBankId>P03438.2</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>132504</SourceOrganismId>
                    </DiscontinuousRegionOnAccessionSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Tables 3 and 4</LocationOfData>
                <EpitopeId>107273</EpitopeId>
                <ReferenceRegion>G135</ReferenceRegion>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Partial Epitope</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 5</LocationOfData>
                        <BCellId>1645147</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000247</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>132504</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>UV-irradiated X-31</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>1 dose of 10,000 HAU followed by a boost with 1,000 HAU 6 weeks later.</DoseSchedule>
                            </FirstInVivoProcess>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>231</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Escape mutants selected with the mAb, derived from human IgM expressing mice, were sequenced to determine the epitope. Also the and its neuramidase treated mAbs were used. This mAb selected residue G151 . The laboratory variants and those selected with other mAbs carrying mutations in the residue were also less well recognized by this mAb in HI and ELISA, confirming the result. The mAb also had no or lower HI activity towards JAP/57 (subtype H2), PR8/34 (subtype H1) and H3 subtype viruses HK/71, PC/73, VIC/75 and TEX/77.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Ascitic Fluid</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>mAb 4.1</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgM</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>132504</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

